Table 1. Characteristics of ACTG 5221 (A5221) Study Population.
| Characteristic | A5221 Cohort |
|---|---|
| N = 21 (%) | |
| ACTG Group Assignment | |
| Early ART | 13 (61.9%) |
| Deferred ART | 8 (38.1%) |
| Median CD4 T-cell count/mm3 (Interquartile range) | |
| Baseline | 131 (35–185) |
| Week 48 | 274 (152–344) |
| Baseline HIV-1 RNA log10 copies/ml | |
| Median | 5.38 |
| Interquartile range | 5.15–5.88 |
| HIV-1 RNA <400 copies/ml (Week 48), N (%) | 21 (100%) |
| TB diagnosis$ | |
| Confirmed | 12 (57.1%) |
| Probable | 9 (42.9%) |
| AFB Sputum Smear | |
| Positive | 10 (47.6%) |
| Negative | 2 (9.5%) |
| Unknown | 9 (42.9%) |
| M. tuberculosis culture | |
| Positive | 7 (33.3%) |
| Negative | 11 (52.4%) |
| Unknown | 3 (14.3%) |
| Site of Infection* | |
| Lungs | 19 (90.5%) |
| Lymph node | 2 (9.5%) |
| Pleural/pericardial | 1 (4.8%) |
$ Confirmed tuberculosis defined by detection of acid-fast bacilli in sputum smear or lymph node sample or by positive culture for M. tuberculosis from sputum, lymph node, or other sterile site. Probable tuberculosis required clinician’s assessment that signs and symptoms warranted tuberculosis treatment.
* Patients may have more than one site of infection